PDCD1 and neoplasm: PD-L1 inhibitors can enhance the body’s anti-tumor immunity by inhibiting T-cell exhaustion caused by the PD-L1/PD-1 axis or other mechanisms, and they have shown to be an effective method for the treatment of a series of tumors, including various intracranial tumors.